Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615661 | 0.83 | THRB (0.52) | SLC13A3THRBHTTRAB9ATSHR | |
| SCHEMBL124955 | 0.81 | ALDH1A1 (0.46) | SLC13A3HTTRAB9ATSHRCHRM5 | |
| SCHEMBL14891772 | 0.77 | SLC13A3 (0.38) | SLC13A3HTT | |
| SCHEMBL12088001 | 0.77 | THRB (0.46) | THRBRAB9ATSHRCHRM5CHRM1 | |
| SCHEMBL8518828 | 0.77 | THRB (0.46) | SLC13A3THRBHTTTSHR | |
| SCHEMBL4797496 | 0.76 | HTT (0.50) | HTTTSHRGLO1 | |
| SCHEMBL8399317 | 0.76 | SLC13A3 (0.34) | SLC13A3THRBHTTTSHR | |
| SCHEMBL608122 | 0.75 | SLC13A3 (0.39) | SLC13A3HTTRAB9A | |
| SCHEMBL14244151 | 0.75 | SLC13A3 (0.32) | SLC13A3 | |
| SCHEMBL26488793 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | OPTIMER PHOTONICS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | INCENP, CYBA, ADCY5 | SLC13A3 3407/4885THRB 4746/4885HTT 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.